Lactea Therapeutics, LLC
Lactea Therapeutics, founded in 2021 in Frederick, MD, is dedicated to advancing naturally occurring, safe, broad-spectrum active molecules as a new class of antibiotic alternatives. Their mission is to reduce the risk of resistance, limit disruption of the microbiome, and decrease the transmission of harmful microbes by harnessing the power of innate immune system proteins. The company leverages patent-pending technology to develop products based on endemic proteins that have evolved to provide broad protection against infections, aiming to translate these natural defenses into pharmaceutical solutions.
Lactea Therapeutics, LLC
Lactea Therapeutics, LLC is currently seeking investment
Lactea Therapeutics, LLC is seeking a series-b investment in the range of 1m-5m
What We Do
A product designed as the first barrier in a layered defense strategy, supporting field dental care by functioning as a barrier to oral biofilms in austere environments where routine hygiene is limited, such as for warfighters.
A portfolio of isolated proteins that are safe, readily available, and do not require cold storage, making them ideal as multifunctional medical countermeasures deployable without specialized training or distribution.
A natural peroxidase enzyme with no known host toxicity, antioxidant properties, and the ability to regulate oxidase activity and degrade reactive oxygen species (ROS) into non-toxic compounds.
Lactea-Lf (MIIP-E2)
A potent, non-toxic, multifunctional innate immune glycoprotein found in all mammals, produced in neutrophils and secretory glands that plays a crucial role in preventing infection early in life. Lactea’s research has focused on harnessing MIIP-E2, for the first time, as a reproducible, safe medical countermeasure which can achieve FDA medical device status (and in the future, biologic) for topical treatments of the skin, wound management, oral and nasal cavities and GI tract against pathogenic bacteria, fungi, and some viruses.
Key People
Christopher Hlubb
CEO
News & Updates
Lactea Therapeutics has developed patent-pending technology to utilize endemic proteins evolved for broad protection, aiming to create new pharmaceutical solutions for infection prevention.